the use of cd20 antibodies in cll patients with notch1 mutations
Published 6 years ago • 349 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
1:21
emerging anti-cd20 monoclonal antibodies as first-line therapy in elderly cll
-
1:48
first-in-class igm based cd20-cd3 bispecific antibody in b-cell nhl
-
1:22
first-in-human study of tg-1801, a cd19/cd47 bispecific antibody ± ublituximab in bcl
-
21:17
new anti-cd20 antibodies for cll - are they better than rituximab?
-
6:00
anti-cd20 antibodies
-
52:58
cd8 t cell immunosurveillance by dr. david masopust
-
3:39
rituxan(rituximab).flv
-
48:09
biocompatibility - ch. 10,11 - cd4 and cd8 t cells
-
3:21
current therapy for cll and the new monoclonal antibody ofatumumab
-
1:42
dose escalation of ro7283420, a hla-a2-wt1 cd3 t-cell bispecific antibody, in r/r aml
-
8:24
cd-20 antibodies in chronic lymphocytic leukemia
-
3:24
adi-001: anti-cd20 car-engineered allogeneic γδ t cells in adults with b-cell malignancies
-
7:04
anti-cd20 antibodies used in treating chronic lymphocytic leukemia
-
3:34
the incidence and clinical correlates of non-immune cytopenia at cll diagnosis
-
3:20
the current standard of care in cml and insights into the use of first- and second-generation tkis
-
4:55
case 1: ibrutinib /- cd20 antibodies in cll
-
18:20
cll: do anti cd20 monoclonal antibodies add to novel agent outcomes?
-
3:48
results from the first-in-human trial of tg-1801 in patients with b-cell lymphoma
-
3:37
cd19/cd20 dual star t-cell therapy for r/r b-all
-
5:07
cd20-targeted antibodies with novel agents for cll
-
3:10
cll treatment: statistical analysis in predictive medicine
-
3:02
euplagia-1: phase i trial of glpg5201, a cd19 car-t product, in r/r cll and richter's transformation